加载中
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
收盘时
US$70.65
−US$0.73 · -1.02%
盘后
US$70.45
−US$0.20 · -0.28%
10月12日 16:58 ET
盘中时间采用ET。市场数据可能有所延迟。
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
日内区间
当前US$70.65
52周区间
当前US$70.65
盘中时间采用ET。市场数据可能有所延迟。
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
日内区间
当前US$70.65
52周区间
当前US$70.65
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 7.94亿 USD | 4.77亿 USD | 3.32亿 USD | 1.69亿 USD | 7841.1万 USD |
| 销售、一般及管理费用 | 1.29亿 USD | 9290.2万 USD | 6070万 USD | 3981万 USD | 2525.9万 USD |
| 营业费用 | 9.24亿 USD | 5.7亿 USD | 4.68亿 USD | 2.32亿 USD | 1.04亿 USD |
| 利息收入 | 1.2亿 USD | 1.1亿 USD | 6290.7万 USD | 835.6万 USD | 34.4万 USD |
| 利息支出 | — | — | — | 2000 USD | 7000 USD |
| 折旧和摊销 | 2486万 USD | 1584.5万 USD | 1017.1万 USD | 945.3万 USD | 345.7万 USD |
| 营业利润 | −9.24亿 USD | −5.7亿 USD | −4.68亿 USD | −2.32亿 USD | −1.04亿 USD |
| 净利润 | −7.67亿 USD | −4.64亿 USD | −4.02亿 USD | −2.23亿 USD | −1亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$122.33
上涨空间 73.15%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.79亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM2.55亿0.33%787.4亿 USD0.19%US$277.88-0.38%
Vanguard Morningstar Small-Cap ETFVB2.02亿0.11%1853亿 USD0.03%US$288.16-0.46%
State Street SPDR S&P Biotech ETFXBI1.4亿1.42%98.74亿 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap Growth ETFVBK1.16亿0.25%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF9279.29万0.10%954亿 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB8058.59万0.74%108.2亿 USD0.44%US$204.26-1.08%
T. Rowe Capital Appreciation Equity ETFTCAF7622.66万0.84%91.1亿 USD0.31%US$43.56-0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBT. Rowe Capital Appreciation Equity ETFTCAFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
